SCHEMBL517832

SCHEMBL517832

CS(=O)(=O)c1ccc([O])cc1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.59
PTGS2 P35354 9/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376239 0.87 ENPP2 (0.72) ENPP2PTGS2
SCHEMBL10300269 0.79 PTGS2 (0.62) ENPP2PTGS2
SCHEMBL17548700 0.79 ENPP2 (0.62) ENPP2PTGS2
SCHEMBL7677302 0.79 PTGS2 (0.62) ENPP2PTGS2
SCHEMBL28182477 0.77 GAA (0.65) ENPP2PTGS2
SCHEMBL12807 0.77 GAA (0.65) ENPP2PTGS2
SCHEMBL8632609 0.75 ALDH1A1 (0.55)
SCHEMBL487226 0.74 ENPP2 (0.56) ENPP2PTGS2
Potassium Ion SCHEMBL1577376 0.74 ENPP2 (0.56) ENPP2PTGS2
SCHEMBL28027 0.74 ENPP2 (0.56) ENPP2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 517 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922350-B Novel benzimidazole compounds and medicinal use thereof 大日本住友制药株式会社 2022-04-19 CN claimed
EP-3348547-B1 BENZIMIDAZOLE DERIVATIVES AS NAV 1.7 (SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT (SCN9A)) INHIBITORS FOR TREATING PAIN, DYSURIA AND MULTIPLE SCLEROSIS SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2020-07-22 EP claimed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 US claimed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 US claimed
EP-2185570-B1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS INC (US) 2014-03-19 EP claimed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP claimed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 US claimed
JP-2010536773-A 2010-12-02 JP claimed
EP-2185570-A2 NOVEL ACTIVATORS OF GLUCOKINASE Metabasis Therapeutics, Inc. (US) 2010-05-19 EP claimed
WO-2009023718-A2 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2009-02-19 WO claimed
WO-1998043969-A1 INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS DUPONT PHARMACEUTICALS COMPANY (US) 1998-10-08 WO claimed
EP-0759929-A4 OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS MERCK & CO INC (US) 1998-09-30 EP claimed
EP-0759929-A1 OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS Merck & Co., Inc. (a New Jersey corp.) (US) 1997-03-05 EP claimed
WO-1995032215-A1 OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS MERCK & CO., INC. (US) 1995-11-30 WO claimed
EP-0339555-B1 WATER SOLUBLE PREPARATIONS OF COCCIDIOSTATICS HOECHST AKTIENGESELLSCHAFT (DE) 1992-12-23 EP claimed
US-5116990-A MAGENTA DYE-FORMING COUPLER FUJI PHOTO FILM CO., LTD. (JP) 1992-05-26 US claimed
EP-0339555-A2 Water soluble preparations of coccidiostatics HOECHST AKTIENGESELLSCHAFT (DE) 1989-11-02 EP claimed
EP-0170164-B1 SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL FUJI PHOTO FILM CO., LTD. (JP) 1988-10-05 EP claimed
US-H122-H PYRAZOLOAZOLE-TYPE MAGENTA COUPLER DISPERSED IN A HIGH-BOILING PHOSPHATE SOLVENT FUJI PHOTO FILM CO., LTD. (JP) 1986-09-02 US claimed
EP-0170164-A2 Silver halide color photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1986-02-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 ENPP2 2324/4885PTGS2 1505/4885
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 ENPP2 2324/4885PTGS2 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.